<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04312347</url>
  </required_header>
  <id_info>
    <org_study_id>TMS01190510</org_study_id>
    <nct_id>NCT04312347</nct_id>
  </id_info>
  <brief_title>Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels</brief_title>
  <official_title>Tamoxifen Dose Adjustment on ER+ Breast Cancer Patients Based on Genomic and Metabolite Concentrations Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nalagenetics Pte Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nalagenetics Pte Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations
      analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations
      based on the CYP2D6 genotypes and endoxifen levels.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of genotype and phenotype of CYP2D6 on plasma and serum concentration of tamoxifen and its metabolites</measure>
    <time_frame>8 weeks after initial tamoxifen intake</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of dose recommendation of tamoxifen based on CYP2D6 genotyping results on endoxifen levels</measure>
    <time_frame>8 weeks after dose recommendation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequencies of CYP2D6 alleles in female Indonesian population</measure>
    <time_frame>Baseline, pre-intervention</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>ER+ Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Personalized dosing of tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increase tamoxifen dose into 40 mg/day for patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen dose adjustment</intervention_name>
    <description>Patients with low endoxifen level and poor/intermediate metabolizer CYP2D6 phenotype will receive tamoxifen dose escalation into 40 mg/day.</description>
    <arm_group_label>Personalized dosing of tamoxifen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with ER+ breast cancer

          -  Have taken tamoxifen daily for at least 2 months

        Exclusion Criteria:

          -  Have not taken tamoxifen daily for at least 2 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baitha P. Maggadani</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmacy, University of Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baitha P. Maggadani</last_name>
    <phone>+62 811-1188-772</phone>
    <email>baitha.p@farmasi.ui.ac.id</email>
  </overall_contact>
  <location>
    <facility>
      <name>MRCCC Siloam Hospital Semanggi</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>12930</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Samuel J. Haryono</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011 May;89(5):718-25. doi: 10.1038/clpt.2011.32. Epub 2011 Mar 23.</citation>
    <PMID>21430657</PMID>
  </reference>
  <reference>
    <citation>Fox P, Balleine RL, Lee C, Gao B, Balakrishnar B, Menzies AM, Yeap SH, Ali SS, Gebski V, Provan P, Coulter S, Liddle C, Hui R, Kefford R, Lynch J, Wong M, Wilcken N, Gurney H. Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study. Clin Cancer Res. 2016 Jul 1;22(13):3164-71. doi: 10.1158/1078-0432.CCR-15-1470. Epub 2016 Feb 4.</citation>
    <PMID>26847054</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>tamoxifen</keyword>
  <keyword>CYP2D6</keyword>
  <keyword>endoxifen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

